Testing effectiveness (Phase 2)Study completedNCT01844765
What this trial is testing
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Who this might be right for
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 59